2 results
Approved WMOSuspended
The aim of this study is to identify whether it is possible to safely discontinue treatment in stable RRMS patients who have shown no evidence of active inflammation in the years prior to inclusion in terms of the return of inflammatory disease…
Approved WMORecruitment started
In the RAINBO POLEmut-BLUE trial, omission of adjuvant therapy will be investigated in very low risk disease and de-escalation of treatment (observation or radiotherapy, but not chemoradiation) in low risk disease.